VanEck Vectors Biotech ETF News

While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se

The macroeconomic backdrop of Fed interest rate hikes is rapidly deflating overvalued technology companies and "crypto-collectibles." We expect the technology sector to underperform value and biotech.

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share b

Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.

Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.

Sector ETF report for BBH

Sector ETF report for BBH

Broadly speaking, mergers and acquisitions in the healthcare sector were steady in 2021, but for many investors, there weren't enough aimed at smaller biotechnology companies. As is often the case, ma

Mogy Joel R Investment Counsel Inc. raised its holdings in shares of VanEck Vectors Biotech ETF (NASDAQ:BBH) by 5.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,036 shares of the company’s stock after purchasing an additional 1,619 shares during […]

We cover dividend stocks often at 24/7, as they provide investors with much better income streams than U.S.

Biotechnology equities are lagging the healthcare sector and the broader market this year, but with new variants of the coronavirus expected to continue popping up in 2022, it's impossible to ignore b

If there's an asset class that's looking forward to 2022, it's small- and mid-cap (SMID) biotechnology stocks because that group dealt with a variety of headwinds this year. However, there are more re

The emergence of the Omicron variant of Covid-19 and inflationary pressure were key highlights of the broader market in November.